Evidence map›Paper›PMID 33292248›Full record

ArticleCancer cell international2020

Characterization and validation of long noncoding RNAs as new candidates in prostate cancer.

Shengyang Ge, Yuanyuan Mi, Xiaojun Zhao, Qingfeng Hu, Yijun Guo, Fan Zhong, Yang Zhang, Guowei Xia, Chuanyu Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Shengyang GeDepartment of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Rd, Shanghai, 200040, P. R. China.
Yuanyuan MiDepartment of Urology, Affiliated Hospital of Jiangnan University, Hefeng Rd, Wuxi, 214000, PR China.
Xiaojun ZhaoDepartment of Clinical Immunology, Shanghai Center for Clinical Laboratory, 528 Hongshan Rd, Shanghai, 200126, P. R. China.
Qingfeng HuDepartment of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Rd, Shanghai, 200040, P. R. China.
Yijun GuoDepartment of Urology, Jing'an District Central Hospital, Fudan University, 259 Xikang Rd, Shanghai, 200040, P. R. China.
Fan ZhongDepartment of Systems Biology for Medicine, and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, 130 Dongan Rd, Shanghai, P. R. China.
Yang ZhangDepartment of Systems Biology for Medicine, and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, 130 Dongan Rd, Shanghai, P. R. China.
Guowei XiaDepartment of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Rd, Shanghai, 200040, P. R. China. xiaguowei@fudan.edu.cn.
Chuanyu SunDepartment of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Rd, Shanghai, 200040, P. R. China. zhugexianglong@163.com.ORCID http://orcid.org/0000-0003-4291-8920
Fudan University · CNShanghai Medical College of Fudan University · CNJiangnan University · CNShanghai Clinical Research Center · CN

Funding

National Key Research and Development Program of China 2016YFB0201702National Key Research and Development Program of China 2018YFC0910700National Natural Science Foundation of China 81372316National Natural Science Foundation of China 81802576
6 · The paper itself

Abstract

backgroundLong noncoding RNAs (lncRNAs) have been proved to be an important regulator in gene expression. In almost all kinds of cancers, lncRNAs participated in the process of pathogenesis, invasion, and metastasis. Meanwhile, compared with the large amounts of patients, there is rare knowledge about the role of lncRNAs in prostate cancer (PCa). MATERIAL/

methodIn this study, lncRNA expression profiles of prostate cancer were detected by Agilent microarray chip, 5 pairs of case and control specimens were involved in. Differentially expressed lncRNAs were screened out by volcano plot for constructing lncRNA-miRNA-mRNA central network. Then, the top ten up-regulated and down-regulated lncRNAs were validated by qRT-PCR in another 5 tumor specimens and 7 para-cancerous/benign contrasts. Furthermore, we searched for the survival curve of the top 10 upregulated and downregulated lncRNAs.

resultsA total of 817 differentially expressed lncRNAs were filtered out by the criteria of fold change (FC) and t-test p < 0.05. Among them, 422 were upregulated, whereas 395 were downregulated in PCa tissues. Gene ontology and KEGG pathway analyses showed that many lncRNAs were implicated in carcinogenesis. lnc-MYL2-4:1 (FC = 0.00141, p = 0.01909) and NR_125857 (FC = 59.27658, p = 0.00128) had the highest magnitude of change. The subsequent qPCR confirmed the expression of NR_125857 was in accordance with the clinical samples. High expression of PCA3, PCAT14 and AP001610.9 led to high hazard ratio while low expression of RP11-279F6.2 led to high hazard ratio.

conclusionsOur study detected a relatively novel complicated map of lncRNAs in PCa, which may have the potential to investigate for diagnosis, treatment and follow-up in PCa. Our study revealed the expression of NR_125857 in human PCa tissues was most up-regulated. Further studies are needed to investigate to figure out the mechanisms in PCa.

Indexed as

lncRNAMicroarrayProstate cancer

Identifiers

PMID33292248
PMCPMC7603695
OpenAlexW3096483722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.